Dongyu Zhang1, Nan Li2, Yuzhi Xi2, Yuan Zhao3, Tengteng Wang2. 1. Department of Epidemiology, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, NC, USA. Electronic address: dzhang34@live.unc.edu. 2. Department of Epidemiology, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, NC, USA. 3. Division of Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract
AIM: Diabetes mellitus (DM) is hypothesized to be associated with an increased risk of ovarian cancer (OC), but current evidences are inconsistent. We aimed to further study this association. METHODS: PubMed, EMBASE, Web of Science, and Scopus were searched for eligible articles. After descriptive summary of the data, a random-effects model was applied in quantitative synthesis. Subgroup analysis was performed by study locales and settings, and sensitivity analysis was conducted based on restrictive selection criteria. Funnel plots and the Egger's test were used to assess publication bias. Statistical heterogeneity in meta-analysis was assessed by the P value derived from the Cochrane Q statistic and I-squared value. RESULTS: Fourteen articles involving data of 15 cohort studies were included for our research. Overall, 17 risk ratios (RRs) were synthesized and yielded a pooled RR of 1.32 (95%CI: 1.14-1.52, PCochrane<0.001, I2=79.8%). Thirteen RRs were synthesized for type 2DM, and the pooled RR was 1.24 (95%CI: 1.06-1.44, PCochrane<0.001, I2=81.8%). Four RRs were synthesized for type 1DM, and the result was significant (RR: 1.83, 95%CI: 1.21-2.78, PCochrane=0.080, I2=55.7%). Results of sensitivity analysis suggested the robustness of a positive association between DM and OC risk, and subgroup analysis demonstrated that the association between DM and OC was much more substantial among Asia population. No publication bias was identified in meta-analysis. CONCLUSION: Our study suggests there is a moderate relative increase in the risk of OC among DM patients. Future studies should investigate the effect of duration of DM and anti-diabetes intervention to OC risk.
AIM: Diabetes mellitus (DM) is hypothesized to be associated with an increased risk of ovarian cancer (OC), but current evidences are inconsistent. We aimed to further study this association. METHODS: PubMed, EMBASE, Web of Science, and Scopus were searched for eligible articles. After descriptive summary of the data, a random-effects model was applied in quantitative synthesis. Subgroup analysis was performed by study locales and settings, and sensitivity analysis was conducted based on restrictive selection criteria. Funnel plots and the Egger's test were used to assess publication bias. Statistical heterogeneity in meta-analysis was assessed by the P value derived from the Cochrane Q statistic and I-squared value. RESULTS: Fourteen articles involving data of 15 cohort studies were included for our research. Overall, 17 risk ratios (RRs) were synthesized and yielded a pooled RR of 1.32 (95%CI: 1.14-1.52, PCochrane<0.001, I2=79.8%). Thirteen RRs were synthesized for type 2DM, and the pooled RR was 1.24 (95%CI: 1.06-1.44, PCochrane<0.001, I2=81.8%). Four RRs were synthesized for type 1DM, and the result was significant (RR: 1.83, 95%CI: 1.21-2.78, PCochrane=0.080, I2=55.7%). Results of sensitivity analysis suggested the robustness of a positive association between DM and OC risk, and subgroup analysis demonstrated that the association between DM and OC was much more substantial among Asia population. No publication bias was identified in meta-analysis. CONCLUSION: Our study suggests there is a moderate relative increase in the risk of OC among DMpatients. Future studies should investigate the effect of duration of DM and anti-diabetes intervention to OC risk.
Authors: Andrea L Buras; Tianyi Wang; Junmin Whiting; Mary K Townsend; Brooke L Fridley; Shelley S Tworoger Journal: Am J Epidemiol Date: 2022-05-20 Impact factor: 5.363
Authors: Ana Babic; Naoko Sasamoto; Bernard A Rosner; Shelley S Tworoger; Susan J Jordan; Harvey A Risch; Holly R Harris; Mary Anne Rossing; Jennifer A Doherty; Renée T Fortner; Jenny Chang-Claude; Marc T Goodman; Pamela J Thompson; Kirsten B Moysich; Roberta B Ness; Susanne K Kjaer; Allan Jensen; Joellen M Schildkraut; Linda J Titus; Daniel W Cramer; Elisa V Bandera; Bo Qin; Weiva Sieh; Valerie McGuire; Rebecca Sutphen; Celeste L Pearce; Anna H Wu; Malcolm Pike; Penelope M Webb; Francesmary Modugno; Kathryn L Terry Journal: JAMA Oncol Date: 2020-06-11 Impact factor: 33.006